Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma.

Katrine PrætoriusDaniel P HenriksenJohannes M SchmidPernille PrintzlauLars PedersenHanne MadsenEhm A AnderssonLouise Klokker MadsenBo L Chawes

Published in: ERJ open research (2021)

This indirect comparison of dupilumab, mepolizumab and omalizumab for patients with severe type 2 asthma fulfilling start-up criteria for more than one drug shows no significant efficacy differences https://bit.ly/3pK9Nf9.

Keyphrases

atopic dermatitis
chronic obstructive pulmonary disease
lung function
early onset
allergic rhinitis
signaling pathway
drug induced
oxidative stress
emergency department
air pollution
immune response
pi k akt
clinical evaluation
inflammatory response
adverse drug